Pharmaust Limited (AU:PAA) has released an update.
PharmAust Limited, a clinical-stage biotechnology company, has released a capital raising presentation and is advancing its research on repurposing monepantel for ALS treatment. With positive Phase 1 study results, they are moving towards a Phase 2/3 study, potentially leading to FDA approval by 2026. The market for neurodegenerative diseases is expected to grow significantly, reaching USD 77.82 billion by 2029.
For further insights into AU:PAA stock, check out TipRanks’ Stock Analysis page.
